Chemical Pathology of Chemerin and Its Link to Obesity and Type 2 Diabetes Mellitus: A Review
Biochemistry and Molecular Biology
Volume 2, Issue 4, July 2017, Pages: 37-39
Received: Apr. 29, 2017; Accepted: Jun. 1, 2017; Published: Jul. 14, 2017
Views 1546      Downloads 95
Authors
Ekpe E. E., Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria
Ekpe V. E., Dornsife School of Public Health, Drexel University, Philadelphia, USA
Article Tools
Follow on us
Abstract
Adipocytokines have been widely recognized in scientific research in recent times because of their varied functions and roles in the body. One of such recognized adipocytokines, is chemerin. A review of chemerin, is presented in this paper with a view to assessing the pathophysiology involved in obesity and type 2 diabetes mellitus. Published literatures were analyzed with the aim of assessing the correlation of chemerin in relation to obesity and diabetes mellitus. Searched literatures and journals from various researchers conclude with the evidence of increased levels of chemerin in type 2 diabetes mellitus patients which might play a major role in the pathogenesis of obesity and type 2 diabetes mellitus. Further studies are needed to understand the factors correlating chemerin levels to obesity and type 2diabetesmellitus. This could enhance pharmacologic management of diabetic and obese patients.
Keywords
Chemerin, Diabetes Mellitus, Obesity, Adipocytokines
To cite this article
Ekpe E. E., Ekpe V. E., Chemical Pathology of Chemerin and Its Link to Obesity and Type 2 Diabetes Mellitus: A Review, Biochemistry and Molecular Biology. Vol. 2, No. 4, 2017, pp. 37-39. doi: 10.11648/j.bmb.20170204.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Conde J, Scotece M, Gómez R, López V, Gómez-Reino JJ, Lago F, Gualillo O (2011). Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011; 37 (6): 413–420.
[2]
Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis. ExpDermatol. 2012 Jan; 21(1):43-7.
[3]
Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J. Am. Acad. Dermatol. 1997; 37(2Pt 3): S18-24.
[4]
Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S. Chemerin--a new adipokine that modulates adipogenesis via its own receptor. BiochemBiophy ResCommun. 2007; 362 (4): 1013-18.
[5]
DuXY, Leung LK. Proteolytic regulatory mechanism of chemerin bioactivity. ActaBiochimBiophys Sin. 2009 Dec; 41(12): 973-979.
[6]
Xhou J, Zhang, Chen N, He H, Ye R. Chemerin C9 peptide induces receptor internalization through a clathrin-independent pathway. ActaPharmacol Sin. 2014; 35(5): 653-663.
[7]
Hah YH, Kim NK, Kim MK, Hur SH, Yoon HJ. Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease. Diabetes Metab J 2011 Jun; 35(3): 248-254.
[8]
Rabe K, Lerhke M, Parhofer KG, Broedl UC. Adipokines and Insulin Resistance. Mol Med. 2008 Nov-Dec; 14(11-12): 741-751.
[9]
Jung UJ, Choi MS. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Non-alcoholic Fatty Liver Disease. Int J Mol Sci. 2014 Apr; 15(4): 6184-6223.
[10]
Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010 Oct; 58(7):883-6.
[11]
Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010 May; 151(5):1998-2007.
[12]
Coimbra S, Brandão Proença J, Santos-Silva A, Neuparth MJ. Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: A close linkage with obesity and length of the disease. Biomed Res Int2014; Article ID 701915, 8pages.
[13]
Roman AA, Parlee SD, Sinal CJ.Chemerin: a potential endocrine link between obesity and type 2 diabetes.Endocrine. 2012 Oct; 42(2):243-51.
[14]
Wang D, Yuan GY, Wang XZ, Jia, L, Di L, L. Yang. Plasma chemerin level in metabolic syndrome. Genetics and Molecular Research 2013; 12(4): 5986-5991.
[15]
Wang LY, Wei L, Yu HY, Zhang Y, Jia WP. Relationship of serum chemerin to obesity and type 2 diabetes mellitus. . 2009 Feb 3; 89(4):235-8.
[16]
Tan X, Li M, Xiao Y. Chemerin correlates obesity and metabolic syndrome and dementia after weight loss in children. Endocrine Abstracts 2016; 41:EP786.
[17]
Li Y, Shi B, Li S. Association between serum chemerin concentration and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLOS ONE. 2014; 9(12):e113915.
[18]
Robert T, Schwarz F, Fischer-Rosisnsky A, Maurer L, Molig M. Chemerin and prediction of diabetes mellitus type 2. ClinEndocrinol 2015; 82(6):838-43.
[19]
Salama FE, Anass QA, abdelnaem AA, saeed E. chemerin: Abiomarker of cardiovascular disease in diabetic chronic kidney diseases patients. Saudi J Kidney Disease Transpl 2016; 27(5):977-984.
[20]
Shehata MA, Ahmed HH, Hameed ER, mokhtar L, Megawer AS. Clinical significance of chemerin in obesity and metabolic syndrome in children. Int Journal of Pharmaceutical and Clinical Research 2015; 7(41):290-295.
[21]
Xu H, Barnes GT, Yang Q, Tan G, Yan D, Chon CJ. Chronic inflammation in fat plays a role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112(12):821-30.
[22]
Ernest MC, Sinai CJ. Chemerin:at the crossroads of inflammation and obesity. Trends in Endocrinology and Metabolism 2010; 21(11):660-662.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186